ArticlePloS one2016
Long Non-Coding RNA-ROR Mediates the Reprogramming in Cardiac Hypertrophy.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Prognostic value of long noncoding RNA ROR in patients with cancer in China: A systematic review and meta-analysis.Medicine · 2019Pooled it
- Running exercise alleviates chronic heart failure by promoting cardiomyocyte autophagic flux through the NEAT1-QKI affecting Beclin1/LC3B mRNA stability.Biology direct · 2026Article
- Orchestrating HFpEF: How Noncoding RNAs Drive Pathophysiology and Phenotypic Outcomes.International journal of molecular sciences · 2025Review
- Roles of Long Non-Coding RNAs in the Pathogenesis of Cardiovascular Disorders: Challenges and Opportunities.Journal of cardiovascular translational research · 2025Review
- Cardiac hypertrophy at the crossroads: Mechanistic insights and emerging multimodal therapeutic strategies.European journal of pharmacology · 2025Review
- Biotechnological Insights into LncRNA-STAT3 Interactions: A Novel Diagnostic Biomarker for Myocardial Hypertrophy.Iranian journal of biotechnology · 2025Article
- The lncRNA Jpx participates in testosterone-induced H9c2 cell hypertrophy by targeting the miR-145-5p/Nfatc3 axis.Frontiers in cell and developmental biology · 2025Article
- Transcriptomics data integration and analysis to uncover hallmark genes in hypertrophic cardiomyopathy.American journal of translational research · 2024Article
- Comparative Analysis of Non-Coding RNA Transcriptomics in Heart Failure.Biomedicines · 2022Review
- Reconstruction and analysis of potential biomarkers for hypertrophic cardiomyopathy based on a competing endogenous RNA network.BMC cardiovascular disorders · 2022Article
- The lncRNA MIAT regulates CPT-1a mediated cardiac hypertrophy through mCell death discovery · 2022Article
- Review
- Dysfunctional network of hub genes in hypertrophic cardiomyopathy patients.American journal of translational research · 2022Article
- LncRNA Gm43843 Promotes Cardiac Hypertrophy via miR-153-3p/Cacna1c Axis.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Long Non-Coding RNAs in Cardiac Hypertrophy.Frontiers in molecular medicine · 2022Review
- Identification of key genes for hypertrophic cardiomyopathy using integrated network analysis of differential lncRNA and gene expression.Frontiers in cardiovascular medicine · 2022Article
- Aerobic Exercise Inhibited P2X7 Purinergic Receptors to Improve Cardiac Remodeling in Mice With Type 2 Diabetes.Frontiers in physiology · 2022Article
- Long Non-Coding RNAs in Cardiovascular Diseases: Potential Function as Biomarkers and Therapeutic Targets of Exercise Training.Non-coding RNA · 2021Review
- Reconnoitering the Role of Long-Noncoding RNAs in Hypertrophic Cardiomyopathy: A Descriptive Review.International journal of molecular sciences · 2021Review
- The function of LncRNA-H19 in cardiac hypertrophy.Cell & bioscience · 2021Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac hypertrophy associated with various cardiovascular diseases results in heart failure and sudden death. A clear understanding of the mechanisms of hypertrophy will benefit the development of novel therapies. Long non-coding RNAs (lncRNAs) have been shown to play essential roles in many biological process, however, whether lncRNA-ROR plays functional roles in the reprogramming of cardiomyocyte remains unclear. METHODOLOGY/PRINCIPAL
findingsHere we show that lncRNA-ROR plays important roles in the pathogenesis of cardiac hypertrophy. In hypertrophic heart and cardiomyocytes, the expression of lncRNA-ROR is dramatically increased, downregulation of which attenuates the hypertrophic responses. Furthermore, the expression of lncRNA-ROR negatively correlates with miR-133, whose expression is increased when lncRNA-ROR is knocked down. In line with this, overexpression of miR-133 prevents the elevation of lncRNA-ROR and re-expression of ANP and BNP in cardiomyocytes subject to phenylephrine treatment. CONCLUSIONS/SIGNIFICANCE: Taken together, our study demonstrates that lncRNA-ROR promotes cardiac hypertrophy via interacting with miR-133, indicating that lncRNA-ROR could be targeted for developing novel antihypertrophic therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.